{"entity":{"id":"nct02908906","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","aka":[],"tldr":"A phase 1/2 trial of Cetrelimab in advanced solid tumours, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers is a phase 1/2 interventional study registered as NCT02908906 by Janssen Research & Development, LLC, with 234 participants enrolled, started 2016-11-21 and due to reach its primary completion in 2023-11-17. Interventions recorded: JNJ-63723283.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02908906","url":"https://clinicaltrials.gov/study/NCT02908906"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cetrelimab"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02908906","phase":"1/2","setting":"63723283LUC1001: A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers","sponsor":"Janssen Research & Development, LLC","enrolled":234,"outcomes":[]},"route":"/trials/nct02908906/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}